bluebird bio Receives EC Approval for SKYSONA™ (elivaldogene autotemcel, Lenti-D™) Gene Therapy for Patients Less Than 18 Years of Age With Early Cerebral Adrenoleukodystrophy (CALD) Without Matched Sibling Donor

bluebird bio Announces Positive Recommendation by PRAC Regarding Article 20 Safety Referral Review of ZYNTEGLO™ Gene Therapy for Transfusion-Dependent β-thalassaemia and Marketing to Resume in EU

bluebird bio marks International Thalassaemia Day 2021: Placing thalassaemia on the agenda of European policy makers

bluebird bio Presents Long-Term Data for elivaldogene autotemcel (eli-cel, Lenti-D™) Gene Therapy for Cerebral Adrenoleukodystrophy (CALD)

bluebird bio Provides Updated Findings from Reported Case of Acute Myeloid Leukemia (AML) in LentiGlobin for Sickle Cell Disease (SCD) Gene Therapy Program

bluebird bio marks Rare Disease Day 2021 with launch of patient testimonial video: ‘Living with Thalassaemia in Europe: Stories from patients of different ages’

bluebird bio Announces Temporary Suspension on Phase 1/2 and Phase 3 Studies ofLentiGlobin Gene Therapy for Sickle Cell Disease (bb1111)

Treatment with Investigational LentiGlobin™ Gene Therapy for Sickle Cell Disease (bb1111) Results in Complete Elimination of SCD-Related Severe Vaso-Occlusive Events in Phase 1/2 HGB-206 Clinical Study Presented at 62nd ASH Annual Meeting and Exposition

Long-Term Data for bluebird bio’s Gene Therapy for β-thalassaemia Show Patients Across Ages and Genotypes Achieve Transfusion Independence and Remain Free from Transfusions Up to Six Years

bluebird bio Announces European Medicines Agency’s Acceptance of Marketing Authorization Application (MAA) for elivaldogene autotemcel (eli‐cel, Lenti‐D™) Gene Therapy for Cerebral Adrenoleukodystrophy (CALD)

bluebird bio’s LentiGlobin™ for Sickle Cell Disease Gene Therapy (bb1111) Granted Priority Medicines (PRIME) Designation by European Medicines Agency

bluebird bio Presents New Results from Clinical Development Programme of elivaldogene autotemcel (eli-cel, Lenti-D™) Gene Therapy for Cerebral Adrenoleukodystrophy (CALD), Including Updated Long-Term Data

New Data Show Near Elimination of Sickle Cell Disease-Related Vaso-Occlusive Crises and Acute Chest Syndrome with bluebird bio’s LentiGlobin™ Gene Therapy for Sickle Cell Disease at 25th EHA Congress

New Data from Phase 3 Studies Support Maintained Transfusion Independence for Patients Across Genotypes Treated with betibeglogene autotemcel▼ (LentiGlobin for β-thalassaemia) Gene Therapy

bluebird bio Announces Launch in Germany of Zynteglo™

bluebird bio Presents New Data Demonstrating Long-Term Transfusion Independence and Safety for LentiGlobin™▼ Gene Therapy for β-thalassaemia across genotypes at ASH Annual Meeting

bluebird bio Presents Data from Phase 1/2 HGB-206 Group C Study Demonstrating LentiGlobin™ Gene Therapy for Sickle Cell Disease (SCD) Produces Anti-sickling Haemoglobin Contributing 40% or More to Total Haemoglobin Following Six Months of Treatment

bluebird bio Presents Updated Data from Phase 2/3 Clinical Study of Lenti-D™ Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) at the 13th European Pediatric Neurology Society (EPNS) Congress

bluebird bio Presents Long-Term Efficacy and Safety Data from Clinical Studies of LentiGlobin® Gene Therapy for Transfusion-Dependent β-Thalassaemia (TDT) at 24th European Haematology Association (EHA) Congress

bluebird bio Announces European Conditional Marketing Authorisation

bluebird bio Receives Positive Opinion from CHMP for Zynteglo™ (autologous CD34+ cells encoding βA‑T87Qglobin gene) Gene Therapy for Patients 12 Years and Older with Transfusion Dependent β‑Thalassaemia (TDT) and Who Do Not Have a β0/β0 Genotype